Capricor Therapeutics reported significant advancements ahead of the anticipated results from the pivotal HOPE-3 Phase 3 study of Daramycin, targeting Duchenne muscular dystrophy, bolstered by a robust safety profile demonstrated across a significant patient population.

• The HOPE-3 study, involving 105 participants, marks one of the largest double-blind trials in Duchenne muscular dystrophy, focusing on non-ambulant patients.
• Safety data from over 800 infusions indicate a consistent safety profile with no new safety signals reported, aligning with the company's commitment to patient safety.
• The company plans to submit HOPE-3 results to address FDA feedback following a Complete Response Letter (CRL) received in July, which stipulated the need for additional evidence of efficacy.
• The FDA has classified the resubmission for Daramycin as Type 2, potentially expediting the review process ahead of a new PDUFA date in 2026.
• Capricor has positioned itself to address unmet medical needs related to Duchenne muscular dystrophy-associated cardiomyopathy, a leading cause of mortality in affected patients.